Basal ganglia (BG) circuitry plays a crucial role in the control of movement. Degeneration of its pathways and imbalance of dopaminergic signaling goes along with movement disorders such as Parkinson disease. In this study, we explore the interaction of degeneration in two BG pathways (the nigro-striatal and dentato-pallidal pathway) with D2 receptor signaling to elucidate an association to motor impairment and medication response.
Introduction
A cell loss in the substantia nigra (compact part; SNpc) due to axonal degeneration has been proposed to be causative for the pathological striatal output [1] . Studies estimated that 40-60% of nigral cells are lost and synaptic function is reduced by up to 80% befor e signs enable ' [2] . On the way to understand the ' w -protective therapies, it becomes more and more obvious, that axonal degeneration even occurs before nigral cell bodies die [1, 3, 4] . Dopaminergic projection axons from the midbrain to the striatum are crucial for locomotion and reward learning with sub-second precision, a function that is ' [5] . An increased vulnerability of dopaminergic axons due to the genetical risk has been discussed to predispose the disease onset [3] . But also an accumulation of misfolded proteins, mitochondrial dysfunction or reactive oxygenic stress yielding to axonal transport impairment, was hypothesized to be involved in the development ' [6, 7] . Here, alpha-synuclein, a presynaptic neuronal protein that is genetically and neuro-pathologically linked to Parkinson's disease, seems to play a specific role in the pathogenesis and the increased vulnerability of dopaminergic axons; the accumulation of this protein has been proposed to specifically alter axonal transport by disturbing e.g. intracellular transport pathways to lysosomes [8] . These findings are in line with results of new antibodies and staining protocols, where alpha-synuclein pathology is abundant in axons and the degeneration begins in the distal axon and proceeds retrograde yielding to an affection of cell bodies [1] . An additional suggestion facilitating the aetiology of parkinsonian symptoms is the special arborisation of nigral neurons and loss of dopaminergic terminals [9] . Especially the long, thin unmyelinated and poorly myelinated axons have been proposed to be the most vulnerable [10] : Dopaminergic neurons of the SNpc are of this type [1] . By influencing the striatal plasticity of medium spiny neurons in the A C C E P T E D M A N U S C R I P T 6 striatum axonal degeneration in the nigro-striatal pathway contributes pathophysiological to ' Phylogenetically, the BG circuitry is an ancient brain structure, comprising of a direct pathway and indirect pathway controlling behaviour like locomotion, reward learning and eye-movement [11] . According to the classical view on BG organisation [12] the striatum is the main input structure of the BG, containing 95% GABA-ergic spiny striatal projection neurons: (1) the first expresses dopamine D1 receptors, is excited by dopamine, and projects directly to the output neurons of the basal ganglia [substantia nigra, reticular part (SNr) and
internal globus pallidus (GPi)] ' w '
basal ganglia. Activation of these neurons is thought to facilitate movement [13] . The second type expresses dopamine D2 receptors, is inhibited by dopamine and ' w '. In this pathway projections are sent via inhibitory, external part of the external globus pallidus (GPe) and the excitatory subthalamic nucleus (STN), which in turn targets the output level of the basal ganglia (GPi and SNr). In contrast to the first pathway, activation of indirect-pathway neurons is thought to reduce movement [13] . A balance between the D1 and D2 system is necessary for sufficient motor control [14] and avoidance-based decisions [15] ; a dysbalance between these two systems might be causative in the development in parkinsonian symptoms [16] influencing the glutamatergic output of the thalamus [17] . It is worth mentioning, that next to striatum, recent studies a lso discuss the STN as an input structure of the BG circuitry via hyperdirect pathway [18] .
In the striatum medium spiny neurons are heterogeneous in their expression of dopamine receptors and their plasticity [19] . Whereas D1 dopamine receptor signalling promotes longterm potentiation [20, 21] , D2 dopamine receptor signalling promotes long-term depression [22] ' w w forms of synaptic plasticity in medium spiny neurons appear to be lost, which suggests that
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7 dopamine receptor signalling is necessary for their induction [21, 22] . Current models of the basal ganglia function herewith emphasize, that balanced activity of medium spiny neurons of both (the D1 and D2) pathways, is required for normal movement, and that movement disorders result from imbalanced pathway activities [23] . Recently, Parker et al., 2018 [24] expanded the classical view and found that normal movement involves activation of clusters of the D1 and D2 system; in the parkinsonian state they found, that D1 activation is reduced and D2 activation is increased. Clusters of activated D1 striatal projection neurons are smaller than in the normal state, and active D2 striatal projection neurons are less clustered, opening a more complex view on the D1 and D2 interplay.
Additional to the D1 and D2 system further satellite systems have been posited to explain ' -motor symptoms [25] : (i) a striato-nigro-striatal loop [26] ' ' j w additional projections to the STN [27] and (ii) multisynaptic connections from the cerebellum, exerting influence on the indirect projection system [28, 29] . Next to the above proposed nigro-striatal system, also the dentato-j ' [30] .
The A1 allele of the D2 (ANKK1) TaqIA (rs1800497) SNP regulates dopaminergic D2 receptor availability [31, 32] , primarily in the striatum. The TaqIA SNP is associated with a mutation producing a single amino acid change within the substrate-binding domain of the ankyrin repeat and kinase domain containing 1 (ANKK1) protein [33] and is in linkage disequilibrium with the D2 receptor locus [34] . Healthy individuals who carry the A1 allele (A1+; risk allele), compared with those who do not (A1-; wild type), have shown diminished striatal D2 receptor density [35] and reduced glucose metabolism in regions involved in reward processing and receiving dopaminergic innervations [36] . Results of the latter studies have, however, to be interpreted carefully due to small sample sizes, methodological
differences, variable effect sizes and because the Taq1A is not located in the D2 gene itself [32, 37, 38] . ' disease has been discussed controversially [39] , meta-analyses of the polymorphism have shown an increased risk of the development of Parkinson' 3 % [40, 41] .
In this study we strive to scrutinize (i) connectivity within BG circuitry in vivo at the example of the nigro-striatal and dentato-pallidal pathway. As diffusion MRI and diffusion tractography has been repetitively shown to be successful in the assessment of macroscopic brain connectivity in vivo [42] , we use this method to assess putative neurodegenerative 
Material and Methods
All tests were performed after informed consent in conformance with the declaration of Helsinki and in accordance to the local ethics committee (http://www.medfak.uni-koeln.de).
The project was divided into three subparts: (i) acquisition of behavioural data, the (ii) determination of gene variants and (iii) the MRI acquisition.
Behavioural data
We included 24, predominantly akinetic-rigid, male PD patients and 24 healthy volunteers matched for age, gender, and handedness as controls in the experiment. The patients were diagnosed with PD according to the Movement Disorder Society diagnostic criteria [43] and therefore subjects without any clinical response to levodopa treatment were excluded from the study. Also patients with relevant concomitant neurological diseases were pre-selectively excluded from the study like patients with signs and symptoms of de mentia, or past history of stroke or brain surgery. There was also no history of toxin exposure, head injury, encephalitis, and metabolic diseases. Due to the fact that gender makes a difference, especially in the analysis of brain connectivity relayed on diffusion MRI, we only included male participants in the study [44] . The 24 healthy controls were acquired in analogous fashion. The behavioural part comprised a video acquisition of the UPDRS, part III. Hence two independent movement disorder specialists rated the UPDRS motor scale (part III) in (a) un-blinded and (b) blinded condition in order to reduce bias by the observers; here the %-responsiveness to standardized soluble L-Dopa (200 mg) was calculated additionally to the degree of motor impairment (reflected by the UPDRS motor scale, part III in the OFF state). Individual rating factors of the observers subjectively influence the UPDRS outcome; an independent and blind rating together with an unblinded rating enhances the reliability of the scoring. We additionally determined the medication response for both gene polymorphisms:
MedResp= Medication Response UPDRS= Unified Parkinson Disease Rating Scale (OFF: after medication withdrawl; ON: with dopaminergic medication)
DD = Disease Duration
Additionally, the disease duration and levodopa equivalent dosage (LEDD) was acquired [45] . In all patients and controls handedness was tested by the laterality index (LI; [46] ) and a dementia was excluded. For further information of the behavioural testing see Supplementary The mask generation of the substantia nigra required a separate procedure in order to reach conclusive evidence in the segmentation o f such a small and heterogeneous brain region [54] : In an initial step we delineated the substantia nigra (SN) by two neuroanatomical experts Before the application of the tractography algorithm, the sizes of all masks [caudate nucleus; dentate nucleus, globus pallidus, putamen, substantia nigra and thalamus] were tested for significant differences between patients and controls in an unpaired sample t-test and in an F-test to compare variances. Mask sizes of the generated masks were analysed in diffusion space (for further details see Suppl. Table 2 ). There were no significant differences in the mask sizes between subjects and patients tested in an unpaired sample t-test (p > 0.05) and no significant differences in an F-test analysis to compare variances (p > 0.05). For further information of the mask development, see Suppl. Figure 4 .
The FDT-toolbox of FSL (version 5.0.4) was applied for tractography [57] . We calculated probability distributions between seeds-and target regions by the application of (3) dentato-thalamo-striato-pallidal and (4) pallido-striato-thalamo-dentatal connections.
The way PROBTRACKX works is that it generates sample "streamlines", or trajectories, to build up a distribution on the location of a connection; this correlates with the anatomical distribution of fibres. Here, we were interested in the probability of the tract starting at A and passing through B. In other words, this is equal to the number of streamlines from A that reaches B (call this K), divided by the total number of streamlines from A (call this N). In order to get K, we run PROBTRACKX with A as a seed and B as waypoint; then K was stored in a text file called waytotal. In order to get N, we multiplied the number of voxels in A by the number of samples per voxel (default=5000):
with ϕ= connection probability starting in A passing through B, K= waytotal, and N= number of voxels in A * 5000 (default).
Connectivity values for the nigro-striatal and the dentato-pallidal pathway were determined w w . The anatomical delineation of the nigro-putaminal pathway (see Suppl. Fig.5 ) was verified by comparison to Carpenter et al., 1972 [58] , who defined -in non-human primates-this tract by starting in the SNpc then passing through the pallidum and to projecting in the putamen [see figure 3B in [58] ]; furthermore, cerebello-thalamo-basal ganglia interconnectivity [59, 60] and the anatomical reliability of tracking the dentato-pallidal pathway (see Suppl. Fig. 6 ) has been 
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Results
We were able to anatomically depict the nigro-putaminal (Suppl. Fig.5 ) and dentatpallidal pathway (Suppl. Fig. 6 ). Our analysis revealed a significant reduction of connectivity in the nigro-striatal (p < 0.003; Fig. 1a ) as well as in the dentato-pallidal pathway (p < 0.0001; Fig. 1c ) in 24 patients compared to 24 healthy controls.
Moreover, we investigated whether a link exists between this decline in connectivity and clinical scales, e.g. the occurrence of motor impairment. To that end, we analysed the association between connectivity measures, the UPDRS -part III-, akinesia and tremor sub- underlying degeneration pattern as compared to the nigro-striatal pathway (Fig. 1d, right) .
To consider the question whether alterations in D2 receptor signalling predicts disease state or dopaminergic treatment response, we tested for an interaction between the respective measures and gene variations in ANKK1. No significant differences between allele-carriers and the wild type were found for any clinical parameter: disease duration, UPDRS-III, akinesia-rigidity, tremor score, or LEDD.
Yet, patients with the A1-variant (i.e., higher striatal D2 receptor availability)
exhibited an association between nigro-striatal connectivity and motor impairment (AR-score:
r=-0.53; p = 0.012; UPDRS-III: r=-0.46; p=0.030; see Fig. 2 ); this was also found for the A1variant in the dentato-pallidal connectivity regarding motor impairment (AR-score: r= -0.62; p = 0.0012). Individuals, with the at-risk A1+ allele (i.e., lower striatal D2 receptor availability) showed no significant alteration in connectivity and motor impairment for both, nigro-striatal and dentato-pallidal connectivity. Remarkably, this effect was reversed relating higher brain connectivity of the dentato-pallidal connectivity (AR: r=0.71; p=0.001; UPDRS-III: r =0.51; p=0.043; Fig. 3 ) to higher motor impairment.
Furthermore, in A1+ ' nigro-striatal connectivity was associated with medication response (r= 0.54; p < 0.02; Fig. 4 ): patients holding the at-risk A1+ variant had only a good medication response when connectivity in the nigro-striatal pathway was high.
For A1-individuals, however, connectivity and medication were negatively correlated, i.e. the therapeutic effect was high, when brain connectivity was low (r=-0.38; p < 0.05).
Discussion
Collectively, with this study we present three important findings: (1) nigro-putaminal and dentato-' decline is associated with impaired motor functionnotably, the decline in dentato-pallidal connections seem to be accelerated in comparison to the putative degeneration of the nigroputaminal pathway; (2) by grouping patients (and controls) according to their ANKK1 genotype, we demonstrate a link between D2 receptor signalling and decline in connectivity in both investigated pathways for the A1-variant (i.e. wildtype). In patients with the A1+ variant, we found increased brain connectivity in the dentato-pallidal pathway (r=0.71;
p=0.001) correlating with increasing motor impairment, suggesting a potentially compensatory function of the cerebellum; (3) finally, differences in D2 receptor availability as predicted by gene variant interact with response to medication and nigro-striatal connectivity, but not cerebellar connectivity.
The nigro-striatal pathway Degeneration of nigro-striatal projections has been described to be highly present in patients with ' [61] . Interestingly, our results from this in vivo study echo the effect of decreased connectivity in nigro-striatal connections in parkinsonian patients during increasing disease duration and motor impairment, as shown by neuro-pathological analyses [62] . We found a linear decrease of nigro-striatal pathway connectivity with increasing akinesia score, as hypothesized in the BG model by Lanciego et al., 2012 [17] . As mentioned above, an additional suggestion facilitating the aetiology of parkinsonian symptoms is the special arborisation of nigral neurons and loss of dopaminergic terminals [9] . Especially the long, thin unmyelinated and poorly myelinated axons have been proposed to be the most vulnerable [10] . It has been suggested that D2 receptor signalling plays a specific role in
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19 modulating the extent of the terminal arbour of SNpc neurons [63] . Our findings underscore ' w erent neurodegenerative patterns for carriers of different variants of the ANKK1 gene. Moreover, dopamine D2 receptors regulate the bridging collateral density from nigro-striatal neurons to the pallidum associated with increased pallidal inhibition. Bridging collateral density modulates herewith the functional balance of basal ganglia circuitry. These findings mirror the complex interplay between influence of gene variants of the D2 receptor and brain plasticity [64] . Our study is to our knowledge the first, which combines structural connectivity with a gene polymorphism implicating in D2 receptor signalling ' disease, and it demonstrates a different degeneration pattern for carriers of different allele variants for nigro-striatal connectivity.
The dentato-pallidal system
The existence of cerebellar projections to the pallidum has been repetitively proven in the macaque monkey [29] , in cats [65] and in healthy humans [48] . In our study dentato-pallidal connectivity revealed a non-linear decline in connectivity following disease severity in PD, which is distinctly different from the decline in the nigro-striatal pathway. An implication of the cerebellum in the dopaminergic system [66] and a structural involvement of the cerebellum in the development of parkinsonian symptoms is well established [67] . Its impact might, however, been under-estimated. Recent findings reported, that nigral dopamine ' w striatal projection neurons in the direct pathway [68] . The cerebellum communicates via thalamus with the striatum and the pallidum [29, 60] . Under physiological conditions, these short latency connections to the BG are capable of facilitating optimal motor control by allowing to incorporate time-sensitive cerebellar information [69] . ' functional MRI studies indicated, that the cerebellum acts as compensatory system to the
20 pathological BG output caused by nigral degeneration [70, 71] . Parkinsonian patients have an impairment to produce self-initiated movements caused by a BG deficiency [72, 73] , especially in patients with akinetic-' [70] . In initial stages of the disease, PD patients are able to sustain externally triggered movements [74] ; the deficiency of self-initiated movements can be compensated by externally triggered tasks, a typical cerebellar function. Interestingly, a recruitment of the cerebello-thalamo-cortical circuit increases concomitant w ' [75] . In more advanced stages compensatory functions break down, but can be maintained by external levodopa supply unt il no modulation of the cerebello-BG interaction is possible [76] . This moved the view away from a cerebellar involvement in the solely generation of parkinsonian tremor, to other dysfunctions like e.g. akinesia or non-motor symptoms [30] . The here described dynamic in decline of this BG satellite system might therefore give additional information to the different clinical presentation of parkinsonian subtypes due to the altered D2 receptor signalling.
Whereas wild type variants of the ANNK1 gene demonstrated a lowered connectivity in both investigated pathways, the group with the at-risk allele showed, however, a different connectivity pattern with no significant decline in the nigro-striatal system, but with an increase of connectivity in the dentato-pallidal pathway following increasing motor impairment. These findings depict a potential compensatory role of the cerebellum differently to the nigro-striatal system in the A1 + group. Our results have, however, to be interpreted carefully due to the unfortunately limited sample size.
D2 polymorphism, motor impairment and medication response
Studies in healthy controls revealed, that the Taq1A polymorphism (rs1800497), representing the A1 allele of the ANKK1 gene, evokes lowered striatal D2 availability in A1+ carriers relative to A1-homozygotes [31, 35, 77] . This polymorphism has been associated with
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21 disorders of self-regulation, such as obesity [78, 79] , addiction [80, 81] and impaired executive function [82] .
' an allelic association between the Taq1A polymorphism and occurrence of the disease exists [40, 83, 84] , although it has been controversially discussed [39] . In our study we quantified connectivity in PD patients in the A1-group and we found lower brain connectivity (with hypothesized higher D2 receptor availability) in the nigrostriatal system than in the A1+ group, having no significant correlation with connectivity for motor impairment.
We also report differences in the medication response relating to the different gene variants. the medication effect of L-DOPA has however been shown on motor and cognitive tasks [87] .
And '
for other D2 receptor polymorphisms (rs2283265 and rs1076560), suggesting a different medication response for the individual gene variants [88, 89] . Next to the medication response also in the appearance of side effects the existence of the D2 receptor polymorphism seems to play a role, as shown for the increased risk of motor fluctuations [90] , dyskinesias [91] or hallucinations [92] . All these examples point towards a more personalized anti-parkinson therapy based on the underlying gene polymorphism. In dependency of the individual gene variants [risk allele (A1+); wild type (A1-)] we found different degeneration strengths in the nigro-striatal system; patients with A1-variant had a significant negative correlation with brain connectivity and the motor impairment (r=-0.53; p=0.012), whereas patients with the risk allele remained non-significant (r=-0.30; p=0.35). In dependency of the individual gene variants [risk allele (A1+); wild type (A1-)] we found antagonistic degeneration patterns in the dentato-pallidal system. Whereas patients with the A1-variant had decreasing connectivity in the dentato-pallidal pathway (r=-0.62; p<0.01), patients with the A1+ variant had an increase of brain connectivity (r=0.71; p<0.01), which might be explained by a (potentially) compensatory role of the cerebellum.
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Figure 4: Influence of ANKK1 gene variants on the medication response
Differences in D2 receptor availability as predicted by the gene variant [risk allele (A1+); wild type (A1-)] interact with response to medication and nigro-striatal connectivity. Due to the reduced receptor density, patients with the risk allele (A1+) had only a good medication response, when brain connectivity in the nigro-striatal system was high (r=0.54; p<0.05); this was reversely found for the A1-group (r=-0.38; p<0.05), where due to the high D2 receptor density a good medication response was even found when brain connectivity was low.
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33 Highlights  Neurodegeneration of the BG circuitry (in nigro-striatal and dentato-pallidal pathways) can be measured by diffusion tractography.
 According to the ANKK1 genotype, different degeneration patterns can be found; particular a potentially cerebellar (compensatory) role for the risk type (A1+).
 Differences in D2 receptor availability interact with response to medication and nigro-striatal connectivity, but not cerebellar connectivity. 
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